Intraventricular Fibrinolysis for Aneurysmal Subarachnoid Hemorrhage.
Model scores of the 29,894 trials active now.
Model score 26% for any early termination, 14% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (381 trials).
Finished trial that started in 2015 or later: the model never saw it during training.
How it ended
Terminated on 2025-02-05, after 2018-02-21 start.
Reason given by the sponsor: “other”
The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-02-05. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Wording of the registration (title, summary, criteria) (raises risk) · Wording
Phrases that raised it: ventricularhemorrhagehoursaneurysmintracranial
Phrases that lowered it: ivfexaminationclinicalcriteria patientstrial to -
Accepts healthy volunteers: No (raises risk) · Who can join
-
Sponsor's past termination rate: 8.8% (raises risk) · Sponsor's track record
-
Drug's FAERS reports with a death: 33.1% (raises risk) · Drug's FDA history
-
Phase: 3 (lowers risk) · Design
-
Has a data monitoring committee: Yes (raises risk) · Design
-
Design: parallel (raises risk) · Design
-
Blinding: single (lowers risk) · Design
-
Sponsor type: academic or other (raises risk) · Sponsor's track record
-
Minimum age: 18 (raises risk) · Who can join
-
Trials the sponsor started in the prior 2 years: 32 (lowers risk) · Sponsor's track record
-
Primary purpose: treatment (raises risk) · Design
-
Disease area, neurology: Yes (raises risk) · Disease area
-
Disease area, cardiovascular: Yes (raises risk) · Disease area
-
Drug's FAERS reports before start: 6974 (raises risk) · Drug's FDA history
-
Disease area, cancer: No (lowers risk) · Disease area
-
Maximum age: 75 (lowers risk) · Who can join
-
Number of arms: 2 (raises risk) · Design
-
Drug's FAERS reports in the prior 12 months: 2065 (raises risk) · Drug's FDA history
-
Collaborators: 0 (raises risk) · Design
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 3 (typical: 2)
- Number of arms
- 2
- Allocation
- randomized
- Design
- parallel
- Primary purpose
- treatment
- Blinding
- single (typical: none)
- Has a data monitoring committee
- Yes (typical: 56% yes)
- Responsible party
- sponsor
- Collaborators
- 0
- Keywords listed
- 5 (typical: 1)
Who can join
- Minimum age
- 18
- Maximum age
- 75 (typical: 71)
- Sex
- all
- Accepts healthy volunteers
- No (typical: 9% yes)
Sponsor's track record
- Sponsor type
- academic or other
- Sponsor's past trials
- 57 (typical: 32)
- Sponsor's past termination rate
- 8.8% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 32 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 2 (typical: 1)
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 6974 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 2065 (typical: 412.5)
- Drug's FAERS reports marked serious
- 84.3% (typical: 85.6%)
- Drug's FAERS reports with a death
- 33.1% (typical: 15.9%)
Disease area and drugs
- Disease areas
- cardiovascular, neurology
- Drugs matched to FDA substances
- alteplase, plasminogen
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III NCT00784134 · started 2009 · scored riskier than 96% of active trials completed
- Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage. NCT02684812 · started 2012 · scored riskier than 83% of active trials completed
- ITCH Trial: Protocol for a Randomized, Double Blind Placebo-controlled Trial NCT04742205 · started 2021 · scored riskier than 48% of active trials completed
- Poststroke Depression in Hemorrhagic Stroke NCT03826875 · started 2019 · scored riskier than 30% of active trials completed
- Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage NCT01787123 · started 2013 · scored riskier than 59% of active trials completed
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.